Overview
News
Salaries
Products
People
Growth
Offices
Financials

Overview

0 Our Vision We aim to redefine what's possible in drug discovery by unlocking the therapeutic potential of synthetic macrocycles (unnatural products) to build a robust, diverse pipeline of valuable medicines. Leadership Cameron Pye, Ph.D.

News

News BioSpace 8 months ago
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Novartis and Unnatural Products did not specify which disease targets they're going after, only noting that the latter's macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
Read more
Report
Press release globenewswire 2 years ago
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology...
Read more
Report

People

Cameron Pye
Executive Officer, Director
Joshua Schwochert
Executive Officer
Vasudev Bailey
Director
Prem Tumkosit
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Santa Cruz United States
HQ
50-200 est. staff

Financials

Total raised
$30.1M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2023 $25M Details
Venture - Series Unknown 2019 $5.1M Details